Drug intelligence / Profile preview

recombinant human insulin patch ZJSRM2021

Development stage: Phase 4
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes
Administration: Transdermal

Overview

ZJSRM2021 is a recombinant human insulin patch designed as a glucose-responsive insulin delivery system. This innovative patch aims to mimic β-cell function by automatically adjusting insulin release in response to blood glucose levels. The technology is designed to improve glycemic control while reducing hypoglycemia risk and injection frequency for patients with diabetes.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on recombinant human insulin patch ZJSRM2021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human insulin patch ZJSRM2021.

Explore the full profile